Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
about
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportTreatment of chronic graft-versus-host disease in 2011Graft-versus-host disease: why have we not made more progress?Chronic graft-versus-host disease (GVHD) in children.Current issues in chronic graft-versus-host disease.Pathogenesis and management of graft-versus-host disease.FFS: an end(point) to our problems in chronic GVHD trials?Failure-free survival after initial systemic treatment of chronic graft-versus-host diseaseThe treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland.Allogeneic hematopoietic cell transplantation: the state of the artComparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.Have we made progress in the management of chronic graft-vs-host disease?How we treat chronic graft-versus-host disease.Biomarkers in chronic graft-versus-host diseaseInfluence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.Treatment of chronic graft-versus-host disease: Past, present and future.A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.Mesenchymal stromal cells: a new tool against graft-versus-host disease?A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group studyPredictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationTreatment and management of graft-versus-host disease: improving response and survival.Acute graft-versus-host disease: new treatment strategies.Notch and inflammatory T-cell response: new developments and challenges.A Canine Model of Chronic Graft-versus-Host Disease.DLL4+ dendritic cells: Key regulators of Notch Signaling in effector T cell responsesMechanistic approaches for the prevention and treatment of chronic GVHD.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
P2860
Q26827651-55E9AD27-F826-4A9A-980C-4DBA6ACD7D93Q26851433-05977AEC-DEC0-4EA5-8C80-80C5E3B260F8Q27012940-78992462-0371-42BD-A286-D8B977030745Q33857680-BF2E61AF-D72D-40B3-A1D7-3E234D7B6D79Q33917187-A8294FD9-FA16-48D3-B7AA-6954A9255F8AQ34077479-B0E3D6E7-7057-4481-8209-421B5A30C7CBQ34077766-639F4077-5F3B-41AB-A3E6-F3EB10C48287Q34077787-A8D29ECA-8D58-4CAA-9C1C-7AFB7A12E8EDQ34082721-2527EA6D-0FBB-44DB-B60D-71D0F55BFAE2Q34145155-FFDA8174-D876-4556-B10E-F7B3B6C776BEQ34279929-3CEB6FEB-8E73-4CFF-936E-D371EBEF6D5DQ34644980-842FFC23-A242-4680-A096-DA5D6DD38B77Q35004923-BFC70F80-D005-46D7-B645-78449634D7ECQ35094374-C7FE2737-C358-41BB-8A1B-5A8D3B18163BQ35112269-D09F2615-FEF8-444E-8603-06315114E97DQ35524687-F7BCE1B6-5590-4319-B479-FF0F4E3F2D98Q35737769-134C54EE-3C87-4ADF-8D04-6D7CFD508A59Q35848391-32C5250D-F0C1-4123-89E6-EE9CA056FC82Q35865095-AC0A9503-B3EE-4F4D-9510-A26440A38A94Q36233448-7D81AD4A-ED99-45B1-B85F-A623F1C55207Q36443116-ACA46A5D-854A-45D6-9631-58836BD16016Q36709850-330648E2-2170-448C-B879-8D950A7E0D62Q36891433-50FB886A-C74A-4425-AB54-6E18D0125F64Q37371836-C832B35F-91DB-4E74-BC65-BFD49C41087CQ37610714-08AE7CFD-3D76-4EF8-A7FA-F77F85945459Q37952793-B14F5F27-78F8-4C6F-A44B-59025C4E8E4EQ38778387-0741E60A-9F5B-41D9-958F-13929DEB1291Q38957582-4AF4B7B5-760D-452F-80E6-93798E8943D3Q39002166-3A0B2E9E-EF72-42D2-9D62-858647B48D7EQ41387926-78B47EE9-503D-489A-B6A5-C93BEBC86EA1Q46428638-4D1C23A4-767E-490E-96D7-C4A92FA48AABQ49724160-AA103460-CDF0-43FC-A086-2570E67FBFD5
P2860
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of mycophenolate mo ...... nic graft-versus-host disease.
@en
Evaluation of mycophenolate mo ...... nic graft-versus-host disease.
@nl
type
label
Evaluation of mycophenolate mo ...... nic graft-versus-host disease.
@en
Evaluation of mycophenolate mo ...... nic graft-versus-host disease.
@nl
prefLabel
Evaluation of mycophenolate mo ...... nic graft-versus-host disease.
@en
Evaluation of mycophenolate mo ...... nic graft-versus-host disease.
@nl
P2093
P2860
P1433
P1476
Evaluation of mycophenolate mo ...... onic graft-versus-host disease
@en
P2093
Barry E Storer
Carrie Kitko
Daniel Weisdorf
John R Wingard
Joseph W Fay
Laura J Johnston
Madan Jagasia
Marcel P DeVetten
Mary E D Flowers
Mukta Arora
P2860
P304
P356
10.1182/BLOOD-2009-02-202937
P407
P577
2009-03-06T00:00:00Z